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To the editor
We report a case of disseminated necrotizing leukoence-
phalopathy (DNL) occurring after alemtuzumab treat-
ment for multiple sclerosis (MS). A 33 year-old female
patient with a 14-year history of highly active, relapsing-
remitting MS despite treatment with interferons, nata-
lizumab and fingolimod was administered 12 mg of
alemtuzumab for five consecutive days. Alemtuzumab
is a humanized monoclonal antibody directed against
the CD52 antigen that significantly reduces relapses,
MRI activity and the rate of sustained accumulation of
disability [1]. Autoimmune disorders such as autoimmune
thyroid disease occur in up to 28 % of patients after
alemtuzumab therapy and are associated with the phase
of immune reconstitution [2, 3]. In addition, respiratory
infections are well known side effects observed in 60 %
of patients [2]. Eight months after treatment, during a
phase of clinically stable MS, the patient was admitted
to the hospital due to anemia with low hemoglobin
which was observed in her for the first time, and warm
autoimmune hemolytic anemia was diagnosed. The
hemoglobin dropped as low as 2.4 g/dl, requiring ther-
apy with corticosteroids, intravenous immunoglobulins,
plasma separation, cyclophosphamide and erythrocyte
substitution. The anemia could not be stabilized. A
lower respiratory tract infection with consecutive septic
shock developed. The patient lost consciousness and re-
quired intubation. No focal neurological deficits were
documented, and due to the fulminant disease course
no MRI was performed. The patient died six days after
admission and a brain autopsy was performed.
Autopsy revealed, besides characteristic inactive MS
lesions, numerous small, round, disseminated and nec-
rotizing lesions in the supratentorial white matter, the
cerebellum and the brain stem including the pons.
These lesions were characterized by numerous axonal
spheroids and a pronounced macrophage infiltrate in
the absence of lymphocytes, consistent with DNL
(Fig. 1) [4, 5].
Severe autoimmune hemolytic anemia has been re-
ported after alemtuzumab therapy, and may be caused
by an immune dysregulation with the development of
autoimmunity following drug application [6, 7]. Paradox-
ically, alemtuzumab is also used to treat autoimmune
hemolytic anemia [6, 8].
The etiology of DNL is still unknown. It was first de-
scribed in patients with brain tumors treated with high-
dose, methotrexate-based chemotherapy and whole brain
irradiation [4, 5]. DNL has been found in immunosup-
pressed patients, including HIV patients [1]. Single case
reports described DNL occurring with infectious diseases
and sepsis, suggesting an excessive inflammatory response
as etiologic factor [9]. Symptoms occur directly after
therapy or many months later [4]. Thus, DNL in our
patient may be related to the direct effects of alemtuzu-
mab, e.g. immunosuppression, or it could be linked to
side effects of alemtuzumab infusions such as the re-
spiratory tract infection with sepsis or the warm
hemolytic anemia and its immunosuppressive treat-
ment. The autopsy showed acute necrotizing lesions,
suggesting they developed simultaneously with the sep-
sis and hemolytic anemia.
Clinical symptoms of DNL include irritability, som-
nolence, rapidly progressive subcortical dementia and
coma with fatal outcome. Neuroimaging may be normal* Correspondence: imetz@gwdg.de
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in early stages and show white matter lesions, often
calcified, in later stages [4]. The observed loss of con-
sciousness in our patient may have been related to
DNL. DNL can be difficult to recognize clinically and is
thus easily overlooked.
In conclusion, the clinician should be aware of DNL as
a possible direct or indirect side effect of alemtuzumab
treatment in MS that is rare but severe, and has never
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Fig. 1 Clinical course and histopathology of DNL as well as MS lesions. The clinical course is illustrated in (a) with the expanded disability status
scale (EDSS, score ranging from 0 to 10 with higher numbers indicating more severe disability), relapses (red arrows) and MS-specific treatment
indicated over time. Clinical stability was achieved with natalizumab (Ntz) and alemtuzumab (Alz), but numerous relapses occurred with interferon
beta-1b (IFNb1b) and fingolimod (FTY) treatment. Eight months after alemtuzumab infusions were given, DNL developed (b-h), characterized by
multifocal disseminated necrotic lesions within the white matter (arrows in b and c, LFB/PAS), but not grey matter (arrowheads in b). In addition
to DNL, typical MS lesions were present (arrowheads in C indicate remyelinated MS lesion). DNL lesions were characterized by acute and
complete tissue destruction with a loss of myelin (d, LFB/PAS), oligodendrocytes and astrocytes (e, anti-GFAP), pronounced axonal damage
(f, anti-APP, insert shows many APP-positive, brown stained damaged axons in higher magnification) and numerous macrophages (g, KiM1P) in
the absence of lymphocytic infiltration (h, anti-CD3). In contrast, MS lesions showed demyelination (i, LFB/PAS) with axonal preservation (not shown),
lymphocytic inflammation (j, anti-CD3) and a sparse infiltrate with macrophages (k, KiM1P). Scale bars represent 200 μm in b (valid for b and c) and d
(valid for d-i and k) as well as 100 μm in j
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